LivaNova PLC
LIVN
Ранг среди акций
#3853
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Цена акции
$78.59
Рыночная капитализация
$4.32B
Изменение (1 день)
-1.40%
Изменение (1 год)
43.65%
Страна
GB
Торговля LivaNova PLC (LIVN)
Категория
Healthcare
Прибыль LivaNova PLC (LIVN)
Прибыль на Jun 2026 TTM: $106.69M
Согласно последним финансовым отчетам LivaNova PLC, текущая прибыль компании составляет $106.69M. В 2023 году компания получила прибыль $-81.33M, меньше, чем прибыли за 2022, которая составила $-75.20M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании LivaNova PLC с 2000 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $106.69M | 20.81% |
| 2024 | $88.31M | -208.58% |
| 2023 | $-81.33M | 8.16% |
| 2022 | $-75.20M | -39.66% |
| 2021 | $-124.62M | -64.22% |
| 2020 | $-348.29M | 172.89% |
| 2019 | $-127.63M | -48.41% |
| 2018 | $-247.40M | -304.29% |
| 2017 | $121.10M | -466.97% |
| 2016 | $-33.00M | -136.96% |
| 2015 | $89.29M | 11.79% |
| 2014 | $79.88M | 6.12% |
| 2013 | $75.27M | 24.58% |
| 2012 | $60.42M | 24.16% |
| 2011 | $48.66M | 26.44% |
| 2010 | $38.49M | 40.21% |
| 2009 | $27.45M | -358.97% |
| 2008 | $-10.60M | -79.26% |
| 2007 | $-51.10M | -13.34% |
| 2006 | $-58.97M | 383.67% |
| 2005 | $-12.19M | -274.42% |
| 2004 | $6.99M | 31.53% |
| 2003 | $5.31M | -119.60% |
| 2002 | $-27.12M | 412.06% |
| 2000 | $-5.30M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| $7.51B | 6,940.15% |
US
|
|
| $5.56B | 5,114.27% |
IE
|
|
| $5.15B | 4,725.28% |
US
|
|
| $3.86B | 3,518.96% |
US
|
|
| - | - |
DE
|
